TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01144442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy with Carboplatin
Description: Carboplatin at a dose of 1000mg/m\^2 will be added to the perfusate once circulating levels reach 1000-1500cc/minute. The circulation of the chemotherapy impregnated perfusate will be performed for 90 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isotonic saline (perfusate)
Description: The HIPC infusion will be performed with a closed abdomen technique. The perfusate will be isotonic saline heated to 40-42° Celsius.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: The abdominal incision will be performed in a vertical fashion extending from the supra-pubic region to around the umbilicus.~If cytoreductive surgery is required, it will be performed at this time and proceed in standard approach.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.
Study: NCT04203628

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xpert MTB/Rif Ultra on stool samples
Description: The Xpert MTB/Rif Ultra will be performed on stool samples processed using four different processing methods:~* Standard sucrose flotation method~* Optimized sucrose flotation~* Stool processing kit (SPK)~* Simple One-step method (SOS)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xpert MTB/Rif Ultra on stool samples
Description: The Xpert MTB/Rif Ultra will be performed on stool samples processed using four different processing methods:~* Standard sucrose flotation method~* Optimized sucrose flotation~* Stool processing kit (SPK)~* Simple One-step method (SOS)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xpert MTB/Rif Ultra on respiratory sample
Description: The Xpert MTB/Rif Ultra will be performed on gastric aspirate or expectorated sputum
Study: NCT03942354

Intervention type: DRUG
Intervention: Bedaquiline
Description: Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.

Intervention type: DRUG
Intervention: Pretomanid
Description: Pretomanid is a nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.

Intervention type: DRUG
Intervention: Moxifloxacin
Description: Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria

Intervention type: DRUG
Intervention: Linezolid
Description: Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.

Intervention type: DRUG
Intervention: Clofazimine
Description: Clofazimine is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.

Intervention type: DRUG
Intervention: Directly observed therapy (DOT)
Description: Standard therapy
Study: NCT04645407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuzheng Huayu tablet
Description: Fuzheng Huayu tablet (0.4g/tablet, 1.6g/time, 3 times/day, oral; take medicine after meals each time)
Study: NCT03076957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-516 Tablet
Description: CKD-516 PO for 5 consecutive days and 2 days off in Combination with Irinotecan inj.
Study: NCT03608579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Adipose Derived Mesenchymal Stromal Cells
Description: Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Adipose Derived Mesenchymal Stromal Cells
Description: Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices
Study: NCT02171260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Eribulin mesylate will be administered intravenously on Days 1 and 8 of each 21-day cycle.
Study: NCT02146547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Administration in once-a-day schedule without regard to meals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole depot
Description: Abilify Maintena is an intramuscular (IM) depot formulation of oral aripiprazole. It provides the efficacy and safety profile of oral aripiprazole in a once-monthly injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone
Description: Administration once a day orally standardised in relation to food intake.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone palmitate
Description: In selected patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilization with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable is needed.
Study: NCT03886220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral; Tablet
Study: NCT04703439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication-taking reminders & educational materials
Description: The intervention has been described in arm/group descriptions, which lasted for 60 days for each participants.
Study: NCT01303822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based day-care clinic group program
Description: 11 weeks of mindfulness-based day-care clinic group program. 6 hours per week.
Study: NCT04476927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiaNose
Description: DiaNose system is an electronic nose device that can smell diseases in the exhaled breath of patients in real time. The recognition of Volatile Organic Compounds (VOCs) in breath samples approach is non-invasive and for safe diagnosis of diseases.~The DiaNose prototype system consists the following elements:~* A Soft Tube connected to a Sensors Chamber - The soft tube is made of medical grade silicon. The subject blows air into the tube for a few seconds and the exhaled air is directed through the sensors chamber. This unit is for single use.~* Sensors Reading Unit- a multi used unit for sensors signals measurement. The Sensor Reading Unit is connected to a Laptop either via a Data Acquisition Instrument - Commercial unit for resistance measurements (https://www.tek.com/keithley-switching-and-data-acquisition-systems/keithley-daq6510) (option A ) or directly by a USB cable (option B).~* Laptop - Laptop is used to activate and save the test measurements.
Study: NCT01761695

Intervention type: OTHER
Intervention: Diagnosed as CML
Description: All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047

Intervention type: OTHER
Intervention: Diagnosed as CML
Description: All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047

Intervention type: OTHER
Intervention: Diagnosed as CML
Description: All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047

Intervention type: OTHER
Intervention: Diagnosed as CML
Description: All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
Study: NCT01966250

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture and usual care
Description: Electroacupuncture: Using 0.25 mm (diameter) X 0.40 mm (length) sized disposable stainless steel needles, electric stimulation will be applied with an electronic stimulator (ES-160, ITO co. LTD, Japan) 2 times/week × 4 weeks. Stimulation will be applied with the current in biphasic wave form. Acupuncture points are Jia-ji (Ex-B2, L3-L5; bilateral) as necessary points and reasonable points (according to decision of practitioner) as accessory points. Each session lasts 15 minutes.~Usual care: Physical therapy and patient education will be performed 2 times per week for 4 weeks. ICT lasts 15 minutes and Hot or Ice pack lasts 10minutes. Doctors will educate patient physiology, pathology, and epidemiology of low back pain. And also suitable postures and exercises for low back pain will be educated.
Study: NCT06584084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WPM-SEMG prototype
Description: Measurements will be done with the rigid matrix. The flexible electrode matrix will be used only on a lower percentage of volunteers depending on the results obtained with the rigid matrix
Study: NCT03372005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Floorball
Description: This intervention will have one week of testing before the first 12 weeks of floorball, followed by one week of testing before the last 27 week training period.
Study: NCT01966250

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care: Physical therapy and patient education will be performed 2 times per week for 4 weeks. ICT lasts 15 minutes and Hot or Ice pack lasts 10minutes. Doctors will educate patient physiology, pathology, and epidemiology of low back pain. And also suitable postures and exercises for low back pain will be educated.
Study: NCT01425398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 40 mg PO qd x 5 days before surgery and then from post-op day 0 to 5.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tab qd x 5d before operation and then from post-op day 0 to 5.
Study: NCT02159794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HLT Transcatheter Aortic Valve System
Description: Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
Study: NCT04703439

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Educational materials
Description: The intervention has been described in arm/group descriptions, which lasted for 60 days for each participants.
Study: NCT01683981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Citrulline Malate
Description: 3 gr per day, oral, for 2 weeks
Study: NCT03451318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate Nasal Spray
Description: Mometasone Furoate Nasal Spray NASONEX

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tonsillar adenoidectomy
Description: tonsillar adenoidectomy
Study: NCT01739192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Subjects will be maintained on oral bupropion or placebo during the study.
Study: NCT03451318

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tonsillar adenoidectomy
Description: tonsillar adenoidectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary expander plus Twin-Block
Description: Twin-block appliance combined with maxillary expander

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary expander plus Twin-Block
Description: Twin-block appliance combined with maxillary expander
Study: NCT01383785

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intracoronary direct injection
Description: Abciximab bolus dosage: 0,125 mg/kg.~Group A: Intracoronary full bolus dose of abciximab proximal to thrombus occlusion. The investigators inject the bolus of abciximab by catheter guide before cross the occlusion. This in the normal way in study' laboratory.
Study: NCT03910673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin disodium
Description: Fosfomycin (a phosphonic acid derivative) formulated as a disodium salt.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin disodium
Description: Fosfomycin (a phosphonic acid derivative) formulated as a disodium salt.
Study: NCT00863031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: problem-solving therapy
Description: Three sessions of problem-solving therapy at week 1, 3 and 5.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Video-viewing
Description: Three sessions of viewing health educational videos.
Study: NCT01943396

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rheohemapheresis
Description: Each treated patient will receive a series of 8 rheohemaphereses (cascade filtration) within 10 weeks. One plasma volume will be washed.
Study: NCT00712764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01032265

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-based treatment with PFMT and elements of CBT
Description: 125 women with stress urinary incontinence(SUI) participate in web-based treatment for 3 months. Treatment consists of information, PFMT and uses elements of CBT. It includes regular email contact with urotherapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pamphlet treatment
Description: 125 women with SUI receive a pamphlet with information and a programme for PFMT.
Study: NCT06370494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living Healthier with Diabetes
Description: Interventions are different aspects of digital health utilizing American Diabetes Association recognized diabetes programs/applications or a combined approach. All participants were randomly assigned to their education arm and received an A1c kit, glucometer, testing strips, and surveys.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living Healthier with Diabetes
Description: Interventions are different aspects of digital health utilizing American Diabetes Association recognized diabetes programs/applications or a combined approach. All participants were randomly assigned to their education arm and received an A1c kit, glucometer, testing strips, and surveys.
Study: NCT01383785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intracoronary and distal injection by aspiration device
Description: Abciximab bolus dosage: 0,125 mg/kg.~Group B: Half bolus of intracoronary abciximab proximal to thrombus occlusion and the other half distal by aspiration catheter. The investigators inject half of the dose like group A and the other half like group C.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intracoronary distal injection by aspiration catheter device
Description: Abciximab bolus dosage: 0,125 mg/kg.~Group C: Distal injection to thrombus occlusion of total bolus dose of abciximab by aspiration catheter. The investigators inject the bolus after cross the occlusion using an aspiration catheter.
Study: NCT02954783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Supervised aerobic High Intensity Interval Training program consisting of 4 weekly sessions of approximately 35 minutes. Patients will perform a test of maximum cardio-respiratory (VO2 peak test). Using the patient's individual wattmax, a personalized exercise program will be prescribed.~After a light warm-up, patients will perform 25 min of aerobic high intensity interval training on a stationary bicycle, intervals will consist of cycles of HI intervals with 120% of wattmax for 1 min followed by recovery for 3 min at 30% of wattmax. Each session will be supervised by trained instructors to ensure proper technique, and progression in training load.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Observational Control
Description: The reference group will receive the standard patient care program as provided by the Department of Urology, Rigshospitalet.This includes information regarding smoking cessation and alcohol reduction and a physiotherapist consultation regarding pelvic floor exercises. This group is allowed to exercise on their own initiative or participate in any standard care hospital- or municipality-based exercise program. This will be monitored by self-report.
Study: NCT01446640

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone marrow derived mesenchymal stem cells
Description: Intravenous administration of up to 1x10\^6 MSCs per kg; intrathecal administration of up to 1x10\^6 MSCs per kg.
Study: NCT01204502

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSVTK retrovirally-transduced donor T lymphocytes
Description: HSVTK retrovirally-transduced donor T lymphocytes will be given at 1 month intervals, providing that there is no significant GVHD~* dose 1 5x104 cells/kg~* dose 2 5x105 cells/kg
Study: NCT02214914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 11634 drinking solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 11634 tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00238914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50mg of oral naltrexone daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50mg of oral naltrexone daily

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Naltrexone Therapy (BNT)
Description: a hybrid of Relapse Prevention, the Community Reinforcement Approach, and Network Therapy
Study: NCT04202822

Intervention type: OTHER
Group type: OTHER
Intervention: Oral soft tissues biopsies
Description: Oral soft tissues biopsies (alveolar mucosa, buccal gingiva, and palatal tissue) will be harvested by the examiner at the time of the surgery (immediately before to start the surgical procedure -T0) and 24 hours after surgery (T24) at the level of the vertical released incisions (VRIs) with a biopsy punch with plunger of 2.0 mm diameter.
Study: NCT06370494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living Healthier with Diabetes
Description: Interventions are different aspects of digital health utilizing American Diabetes Association recognized diabetes programs/applications or a combined approach. All participants were randomly assigned to their education arm and received an A1c kit, glucometer, testing strips, and surveys.
Study: NCT05511636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Description: This study will be conducted on 180 patients who will be undergoing lung resection (wedge resection, segmentectomy, metastasectomy, lobectomy, or pneumonectomy) surgery at the Cardiothoracic department, Ain Shams University Hospitals; patients are to be extubated intraoperative, and at the ICU we will be comparing HFNC to standard oxygen therapy. The endpoints of the study are to investigate whether high-flow nasal cannula oxygen therapy is superior to conventional oxygen therapy for reducing hypoxemia and postoperative pulmonary complications in extubated patients after lung resection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Description: This study will be conducted on 180 patients who will be undergoing lung resection (wedge resection, segmentectomy, metastasectomy, lobectomy, or pneumonectomy) surgery at the Cardiothoracic department, Ain Shams University Hospitals; patients are to be extubated intraoperative, and at the ICU we will be comparing HFNC to standard oxygen therapy. The endpoints of the study are to investigate whether high-flow nasal cannula oxygen therapy is superior to conventional oxygen therapy for reducing hypoxemia and postoperative pulmonary complications in extubated patients after lung resection.
Study: NCT03366935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EPL and CEI
Description: Procedure: Standard epidural placement(EPL)~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to continuous epidural infusion(CEI) plus patient-controlled epidural analgesia (PCEA).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DPE and CEI
Description: Procedure: Dural puncture epidural (DPE) Epidural with spinal needle placed to create a single dural puncture and confirm free flow of cerebral spinal fluid (CSF) , without direct medication administration into the subarachnoid space.~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to continuous epidural infusion(CEI) plus patient-controlled epidural analgesia (PCEA).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DPE and PIEB
Description: Procedure: Dural puncture epidural (DPE) Epidural with spinal needle placed to create a single dural puncture and confirm free flow of cerebral spinal fluid (CSF) , without direct medication administration into the subarachnoid space.~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
Study: NCT04318509

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GMPOWER
Description: (casein) glycomacropeptide protein substitute for the dietary management of PKU from the age of 3 years
Study: NCT04803656

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of COPD patients
Description: Assessments explained in the arm section were made as described in one session.
Study: NCT03114709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindful Movement
Description: The program focuses on enhancing individuals' mindfulness capabilities and skills, specifically attention regulation, body awareness, emotional regulation, and shifts in self-perception, by providing opportunities for education, practice, and social support in mindfulness practices and physical activity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10 Keys to Health & Wellbeing
Description: This community-based educational program provides participants useful content focused on general health related topics including common chronic conditions, social support, social participation, cancer screening, immunization and keeping active.